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Platelet-rich Plasma (PRP) is a fascinating biological treatment showing promising results for the management of
cartilage disorders. However, despite the step forwards in this research area and the increasing use of PRP in clinical
practice, its use remains still controversial and especially its application as injective treatment for ankle cartilage
pathology have been scarcely investigated.
The aim of this paper is to describe the translational evidence for the use of PRP in cartilage treatment and to
systematically review all the available evidence regarding the clinical application of PRP for ankle cartilage disorders,
in order to understand what is the current state of the art for this specific clinical indication, underlining both limits
and potential of this biological strategy.
A systematic review of the clinical literature was performed on the use of PRP to treat ankle cartilage disorders and
7 papers were identified. PRP has been used in two different ways: 5 of the available papers focus on its use as an
augmentation procedure to various surgical techniques for cartilage regeneration, while only two studies report its
conservative application through intra-articular injections. Based on the limited number of clinical studies available
on this topic, this systematic review showed the lack of major adverse events related to PRP and overall good
results for the treatment of ankle cartilage pathology, thus confirming the translational potential of this biological
treatment suggested by several preclinical studies. Further high quality clinical trials in the ankle are still needed to
clarify proper indications and best applicative modalities.
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Platelet-rich Plasma (PRP) is a fascinating biological treat-
ment showing promise for the management of cartilage
disorders [1,2]. The possibility of using autologous blood
to obtain a product rich in growth factors and other
bio-active molecules involved in tissue healing has been
regarded as an innovative approach that could be sided
to classical “on-the shelf” products from pharmaceutical
companies.
The first reports in this field of application were pub-
lished 10 years ago and since then many studies have been
made in order to understand the biological effects of PRP
and the potential and limits of this approach, not just as a* Correspondence: berardo.dimatteo@gmail.com
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in any medium, provided the original work is ptherapeutic strategy for cartilage pathology [3,4] but more
in general for a wide range of musculo-skeletal disorders,
such as ligament and tendon pathologies [5-7]. However,
despite the step forwards in this research area and the in-
creasing use of PRP in the clinical practice, its use remains
still controversial, especially its application as a treatment
for ankle cartilage pathology [6].
In fact, under a clinical point of view, the vast majority
of the studies already published is focused on the appli-
cation of PRP in the knee joint, whereas only a smaller
number of studies deals with other joints such as hip
and ankle, either as a conservative injective approach or
as an augmentation during surgical procedures for cartil-
age repair [8-11]. Thus, the rationale for the use of PRP in
the ankle is currently mainly derived from the knee ap-
plication. Among the available knee focused studies, 4
double blind randomized controlled trials show promisingan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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of PRP [12-15]. PRP has been shown to provide a superior
clinical outcome with respect to placebo (saline solution),
thus proving a real clinical benefit [15]. More controversial
is the superiority of the results obtained compared to
other treatments: when compared to viscosupplementa-
tion, results are not that promising and there is some
support but no conclusive evidence that PRP is signifi-
cantly better than hyaluronic acid (HA) for the treatment
of cartilage pathology [12]. The overall literature suggests
that PRP is at least as effective as HA and should be there-
fore considered one of the available options for knee car-
tilage treatment. While knee pathology can be considered
a bench test for all articular locations, other joints have
been less enquired by researchers.
The aim of this paper is to describe the translational
evidence for the use of PRP in cartilage treatment and to
systematically review all the available evidence regarding
the clinical application of PRP for ankle cartilage disorders,
in order to understand what is the current state of the art
for this specific clinical indication, underlining both limits
and potential of this biological strategy.Figure 1 Prisma 2009 flow diagram describing the papers selection pReview
Materials and methods
A systematic review of the literature was performed on
the use of PRP to treat ankle cartilage disorders. The
search was made on the PubMed database on October
10th, 2014 using the following formula: (PRP OR platelet
rich plasma OR platelet concentrate OR PRGF OR plate-
let gel OR platelet derived growth factors) AND (ankle or
tibio-talar or talar) AND (osteoarthritis OR chondropathy
OR chondral lesions OR osteochondral lesion). The guide-
lines for Preferred Reporting Items for Systematic Reviews
and Meta-analysis (PRISMA) were used [16]. The screen-
ing process and analysis were performed separately by 2
independent researchers (Figure 1).
First, the articles were screened by title and abstract.
The following inclusion criteria for relevant articles were
used during the initial screening of titles and abstracts: clin-
ical reports of any level of evidence, written in the English
language, with no time limitation, on the use of PRP to
treat ankle cartilage disorders. Other exclusion criteria
were: case reports, articles written in other languages,
animal trials, and reviews. In the second step, the fullrocess.
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exclusions according to the previously described criteria.
Moreover, articles not reporting clinical results were ex-
cluded. Reference lists from the selected papers were also
screened. Relevant data were then extracted and collected
in a single database with consensus of the two observers
to be analyzed for the purposes of the present manuscript.
At the end of the process, 7 papers fulfilled the selec-
tion criteria and have been described in the following
paragraph.
Results
PRP application, as reported in the literature for cartilage
disease treatment in the ankle joint, can be summarized in
two treatment strategies. Five papers focus on its use as an
augmentation procedure to various surgical techniques for
cartilage regeneration, while only two studies report its
conservative application through intra-articular injections
(Table 1).
Conservative application
Conservative application of PRP was firstly reported in a
prospective randomized study by Mei-Dan et al. [17], who
compared the efficacy of hyaluronic acid (HA) and PRP in
30 patients (15 per group) affected by talar osteochondral
lesions not responsive to previous conservative manage-
ment. Patients were divided into 2 groups: one to receive
3 weekly intra-articular injections of HA (2 ml each); the
other one to receive PRP (2 ml each) with the same ad-
ministration protocol. They were evaluated for up to
28 weeks of follow-up: AHFS (Ankle Hindfoot Score),
AOFAS (American Orthopaedic Foot and Ankle Score),
and VAS (Visual Analogue Scale) were used to test pain,
stiffness and function, showing that PRP was significantly
more effective at controlling pain and re-establishing
function.
The conservative approach was also described by
Angthong et al. [18], who applied PRP to different foot
and ankle diseases and, among them, to low grades of
ankle OA. PRP was injected under fluoroscope or ultra-
sound guidance and results were evaluated by VAS-FA
(VAS Foot and Ankle) score. Patients with OA were also
studied radiographically and scored for the OA grade. The
5 patients with OA included in this study presented a sig-
nificant improvement in their clinical conditions accord-
ing to VAS-FA score at a mean follow-up of 16 months
(calculated on the whole series of patients). Despite the
improved clinical condition, no changes in the degree of
OA was evident on MRI 5 months after PRP injection.
Surgical application
The surgical application of PRP as augmentation to micro-
fractures in full thickness osteochondral lesions of the
talus has been investigated by Guney et al. [19] in the onlyrandomized comparative study available on this specific ap-
plication modality: 35 patients were scheduled to receive ei-
ther microfracture alone or microfracture in association with
PRP (a single injection after 6–24 hours from arthroscopic
microfractures), and were assessed at 16.2 (12–24) months
follow-up using the AOFAS scoring system, Foot and
Ankle Ability Measure (FAAM), and the VAS for pain.
At baseline, AOFAS and FAAM scores were similar in
the two groups, whereas pain scores (VAS) were higher
in those who were assigned to the combined treatment.
Despite the latter finding, the combined treatment with
PRP resulted in significantly better outcomes in terms
of functional scores (AOFAS, FAAM overall pain domain,
FAAM 15-min walking domain, and pain-related scores)
when compared to bone marrow stimulation alone. The
authors concluded that PRP as an adjunct to arthroscopic
microfracture surgery for the treatment of osteochondral
lesions of the talus resulted in improved functional score
status in the medium-term evaluation.
The most common surgical application of PRP involved
its use as augmentation to scaffold implantation. This strat-
egy for the treatment of full thickness talar osteochondral
lesions has been documented by Giannini and his group in
four different studies [20-23]. They described the clinical
application of an arthroscopic one-stage technique involv-
ing autologous mesenchymal stem cells (MSCs), PRP, and
either porcine collagen powder or HA membrane. The
procedure consisted of harvesting bone-marrow-derived
cells from the posterior iliac crest of the patients through
a traditional marrow needle. Sixty ml of bone marrow-
aspirate were collected and immediately put into a cell
separator-concentrator to obtain a final 6-ml concentrate
of MSCs. A collagen powder or a HA membrane could
then be used. In the former cases, 2 ml of MSCs concen-
trate was added to 1 g of collagen powder and 1 ml of
platelet-rich fibrin gel (obtained the day before surgery).
In the latter cases, HA membrane was cut to match the
size of the talar ostechondral lesion and then covered with
2 ml of MSCs concentrate and 1 ml of platelet-rich fibrin
gel. The entire procedure was performed via ankle arth-
roscopy and, after the preparation of the lesion, the bio-
logical composite was placed in the defect site through a
cannula and using a probe to obtain the best possible fit.
The first prospective single-arm clinical trial [20] in-
volved 48 patients (mean age = 28.5 years) affected by
focal lesions (mean size = 2.1 cm2) and evaluated at 6, 12,
18, and 24 months of follow-up using the AOFAS score. A
significant increase in this parameter was recorded 6
months after the surgical procedure, and this outcome
was confirmed up to the final follow-up. The rate of re-
turn to high impact sport activity was satisfactory: more
than 75% of the patients returned to sport at 11 months
of follow-up. The investigators found a correlation be-
tween clinical outcome and lesion size: poorer results
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Table 1 Synopsis of all the clinical studies on PRP application in ankle cartilage pathology (Continued)
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was also shown to affect the outcome negatively. Con-
versely, the outcome was not influenced by the lesion
depth or by the type of scaffold used (collagen powder
or HA membrane). Five second-look arthroscopies were
performed at 1 year follow-up: in 2 cases biopsies were
taken, revealing, after histologic and immune-histologic
analysis, the presence of new cartilage tissue with varying
degrees of tissue remodeling towards a hyaline aspect. The
overall findings suggested that this novel approach could
stimulate tissue regeneration with promising clinical effi-
cacy, thus providing results that may even be comparable
to those of autologous chondrocyte implantation (ACI)
while avoiding the double surgical time and the inherent
stress for the patient.
The same authors performed a further study [21] to com-
pare MSCs + PRP + scaffold with open and arthroscopic
ACI. Eighty-one patients were included in this analysis, and
three different treatments were compared: 10 patients were
treated by open ACI, 46 by arthroscopic ACI, and 25 by the
bone-marrow-derived mesenchymal cells “one-step” tech-
nique. The clinical results were compared for up to 3 years
of follow-up. AOFAS was the test chosen for clinical evalu-
ation and radiographic analysis was performed as well. The
clinical improvement in each subgroup was significant and
no inter-group difference was observed, thus confirming
the possibility of matching the effectiveness of chondrocyte
transplantation by a single-step procedure. X-Rays showed
no sign of OA progression and MRI revealed a good rate of
defect filling and integration of the newly regenerated tissue
within the surrounding tissue. Another aspect worth con-
sidering is the economic one: in fact, the authors pointed
out that their novel one-step regenerative technique costs
less than a half than traditional arthroscopic ACI.
An MRI evaluation was performed by Battaglia et al.
[22] at 2 years’ follow-up from surgery in a selection of
20 patients operated by this one-step technique. MRI
images were acquired using, beside a protocol suggested
by the International Cartilage Repair Society and the
MOCART scoring system, a T2 mapping qualitative
sequence. Results were then correlated with AOFAS
clinical score, which showed a significant improvement
from pre-operatively to 2 years of follow-up. The T2
relaxation time value of 35–45 ms was derived from
healthy ankles evaluation and assumed as normal hya-
line cartilage value and used as a control. Regenerated
tissue with a T2 relaxation time value comparable to
hyaline cartilage was found in all the treated cases, cover-
ing a mean of 78% of the repaired lesion area. A high clin-
ical score was directly correlated to iso-intense signal in
DPFSE fat sat and to the percentage of regenerated
hyaline cartilage, and inversely correlated to the
percentage of newly formed fibrocartilage. Lesion’s
depth was negatively correlated to the integrity of therepaired tissue’s surface and to the percentage of regen-
erated hyaline cartilage.
Finally, the same original case series of 49 patients was
clinically evaluated at a further follow-up of 4 years [23].
The overall AOFAS score improved significantly, with best
results at the 24-month follow-up. A significant decrease
in the clinical score was observed between 24 and 36
months postoperatively and between 24 and 48 months in
the general case series. Nevertheless, while evaluating the
20 patients who performed T2 mapping MRI 2 years be-
fore, it was evident a significant relationship between the
AOFAS score at 48 months’ follow-up and the percentage
of regenerated cartilage with hyaline features (T2 value of
35–45 ms). Patients with hyaline-like regenerated cartilage
in more than 80% of the treated area had a more predict-
able and stable result.Discussion
The results of this systematic review show the lack of
major adverse events related to PRP, and overall good re-
sults for the treatment of ankle cartilage pathology, either
as conservative approach or as augmentation to surgical
procedures, thus confirming the translational potential of
this biological treatment suggested by several preclinical
studies and also in this limited number of clinical trials re-
garding the ankle joint.
The literature exploring the potential of PRP in the
preclinical setting underlined different aspects that could
explain the positive clinical findings obtained with this
blood derivative (Table 2).
In vitro studies investigating the effect of PRP on
chondrocytes showed various and heterogeneous mecha-
nisms of action [24-26]. Most of these studies agreed in
reporting an increased chondrocyte proliferation rate, while
the maintenance of chondrocyte marker expression has
been observed in several papers but not unanimously con-
firmed. Other effects ranged from the matrix production
stimulation to the inflammation modulation, and some
findings even suggested a potential role of PRP as anal-
gesic compound by modulating cannabinoid receptors in
chondrocytes [27].
Beside the direct effects on chondrocytes, to understand
the translational potential of PRP it is also important to
consider the overall role played by PRP in affecting the en-
tire joint homeostasis, as demonstrated by studies focused
on different cell types. Platelet concentrates may signifi-
cantly enhance synoviocyte HA secretion and switch
synovial angiogenesis to a more balanced status, even
though some reports also suggest some potential draw-
backs, likely related to the leukocyte content, due to the
metallo-proteinases production and therefore a possible
pro-inflammatory response that could lead to an acceler-
ated cartilage catabolism [28].
Table 2 Summary of the findings from in vitro and
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effects also when applied
together with microfractures
Pig [37] - In Rheumatoid Arthritis model:
overall reduction in pro-flogistic
Table 2 Summary of the findings from in vitro and in vivo




Horse [34] - In OA model: positive
modulation of joint
homeostasis, with reduction
of lameness and joint effusion
up to middle term evaluation
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derives from an interaction with the pre-existing environ-
ment and other cells, and since some surgical protocols
involve the application of both platelets and cells, several
studies also investigated the effect of PRP on MSCs of dif-
ferent origin. In all cases an overall stimulatory effect was
documented, ranging from a chemotactic action to an
increased proliferation, and from the chondrogenic dif-
ferentiation to the production of molecules specific of
the articular cartilage [29,30].
Preclinical studies also explored the rational for PRP use
and tested its translational potential in the animal model,
with interesting findings in both an acute and chronic
lesion setting. Induced OA was treated with PRP injec-
tions showing heterogeneous results in different experi-
mental models: while some authors showed no significant
effects in the rat model, others suggested an indirect effect
through the induction of other cells and a final better
histological appearance [29,31]. More concordant and
favorable results have been seen in bigger animal models,
with a suppression of OA progression or even tissue re-
generation in rabbits [32,33], and a significant improve-
ment of degree of lameness and joint effusion treating OA
in horses [34].
The treatment of acute chondral or osteochondral lesions
has also been documented [35,36]. In these experimental
settings, PRP seemed to provide an overall beneficial effect
when used as an injective approach or even when applied
after microfracturing. The findings emerged from these
animal studies showed that PRP was able to increase
macroscopic, histologic and biomechanical scores, al-
though a full restoration of hyaline cartilage has not been
shown. Furthermore, PRP was also tested in the pig
rheumatoid arthritis model [37], revealing an anti-
inflammatory potential and a chondroprotective effect
that would be worthy of more studies to understand the
contribution of PRP as topical therapy even in this
more complex immunological disease.
Beside the positive effects of this therapy demonstrated
by most of the preclinical in vitro and animal studies,
many questions remain still open and how to manage the
numerous variables that could optimize PRP translational
potential is still controversial.
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ables related to the product, such as dose, cell content,
activation method and storage procedures, as well as
application modality and concomitant procedures [38].
First of all, PRP dose could be of particular importance
for the outcome since it is strictly linked to the amount
of growth factors and bioactive molecules administered.
Both in vitro and animal studies showed a time-dependent
regulation and the dose-dependency effect of PRP, sug-
gesting that a better clinical outcome can be achieved in
function of the platelet count [26,39]. However, beside
the amount of platelets, another and more debated aspect
could play a major role for the intra-articular application
of PRP: cell content, which is the most controversial as-
pect, especially with regard to the presence of leukocytes.
In fact, even though leukocyte presence could contribute
to an anti-microbial effect [40], some in vitro studies have
shown that leukocyte rich PRP stimulates expression of
pro-inflammatory molecules and enzymes detrimental for
joint homeostasis [41]. Nonetheless, from a clinical point
of view there is a lack of studies addressing this question
with a proper methodology and, looking at the current
evidence, it has not been demonstrated any significant
clinical difference according to PRP formulation, with the
exception of post-injective adverse events (more pain and
swelling after leukocyte-rich PRP administration) [42]. Ac-
tivation methods and storage procedures are also aspects
under examination: in particular, activation has been dem-
onstrated to affect the physical properties and growth fac-
tors release kinetics of PRP [43], even if no data have been
reported about differences in clinical results. For what
regards storage methods, a recently published in vitro
trial revealed that freeze thawing is a safe procedure,
which sufficiently preserves PRP quality and its ability
to induce proliferation and the production of extra cel-
lular matrix (ECM) components in both chondrocytes
and synoviocytes [44]. The possibility to preserve PRP
could be relevant in the clinical setting since multiple
injections of PRP can be required in case of poor response
or symptom relapse, and this strategy is therefore attract-
ive: a single blood harvesting can contribute to reduce
costs and patient’s discomfort. However, therapeutic pro-
tocols (i.e.: number of PRP injections and their timing) are
still a controversial point, where poor evidence is available,
and clinicians tend to adopt very personal approaches,
mainly based to their personal experience with other
injective products [38].
In conclusion, the translational evidence currently avail-
able is overall supporting the application of PRP as a treat-
ment option for both focal chondral/osteochondral lesion
and for joint degenerative pathology, due to the milieau of
effects exerted by PRP on all the articular tissues. For
sure the great variability among PRP formulations, re-
ported by in vitro studies, still remains the main issueto address in order to develop the best product for spe-
cific clinical use.
Looking at the available evidence on the clinical bene-
fit obtained with this blood derivative, the application of
PRP to treat ankle cartilage pathology is supported by 7
studies: 5 of them dealing with surgical treatment and two
with an injective approach [17-23]. The randomized trial
by Mei-Dan et al. [17] revealed significant results in favor
of PRP but the low number of patients and the short-term
follow-up evaluation are weak points, while the study by
Angthong et al. [18] deals with the use of PRP in different
foot and ankle pathologies and just 5 patients were actu-
ally affected by ankle OA. Conversely, the studies testing
the surgical application of MSCs + PRP + biomaterials
(collagen powder or HA membrane) [19-23] are well
documented but the value in determining the actual
role of PRP is limited because in all of them it is
described the combined use of multiple biological au-
tologous and bio-engineered substances, without con-
trol groups, so that it is impossible to determine the
actual contribution of PRP itself to the success of the
procedure [9].Conclusion
PRP is certainly a fascinating area of pre-clinical and
clinical research. Nonetheless, at present, there is a very
limited number of studies regarding the use of PRP for
ankle cartilage pathology, since only one Level I trial is
available and the surgical application, although particu-
larly successful, relies in the majority of the cases on a
combination of different factors.
Many “shadow lines” must be addressed: PRP cannot
still be univocally defined and, up to now, there are too
many different PRP formulations applied in clinical prac-
tice. The many inter-products differences previously dis-
cussed and related to preparation methods, cell content,
activation and storage procedures, therapeutic protocols
and others, reflect the complexity of this biological treat-
ment and justify the difficulties in data comparison
among studies and the inherent lack of clear indications
about PRP therapy. Despite these limitations, this vari-
ability has stimulated a large interest of basic scientists
and clinicians to explore what are the best characteris-
tics of PRP to treat specific diseases, and many studies
are ongoing to further improve this biological treatment
approach. However, regardless of the golden aura around
its therapeutic potential, until further studies will prove
the real translational potential of the promising results
suggested by preclinical in vitro and animal studies, thus
optimizing its use and identifying the best indications
in the clinical practice, PRP should be considered a sec-
ond line treatment and applied in humans within well
controlled studies.
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